Best Practice & Research Clinical Rheumatology
Volume 23, Issue 3 , Pages 419-428 , June 2009

Cardiovascular involvement in primary systemic vasculitis

  • Chetan Mukhtyar, MBBS, MRCP (UK) (EULAR Research Fellow)

      Affiliations

    • Rheumatology Department, University of Oxford, Oxford, UK
    • ,
  • Paul Brogan, BSc(Hon), MBChB(Hon), MRCPCH, MSc, PhD (Senior Lecturer in Paediatric Vasculitis)

      Affiliations

    • Paediatric Rheumatology Department, Institute of Child Health and Great Ormond Street Hospital, London, UK
    • ,
  • Raashid Luqmani, DM, FRCP, FRCPE (Senior Lecturer in Rheumatology)

      Affiliations

    • Rheumatology Department, University of Oxford, Oxford, UK
    • Corresponding Author InformationCorresponding author. Rheumatology Department, Biomedical Research Unit in Musculoskeletal Science, Botnar Research Centre, Windmill Road, Oxford, OX3 7LD, UK.

References 

  1. Fries JF, Hunder GG, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary. Arthritis Rheum. 1990 Aug;33(8):1135–1136
  2. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994 Feb;37(2):187–192
  3. Lanham JG, Elkon KB, Pusey CD, Hughes GR. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore). 1984 Mar;63(2):65–81
  4. Watts R, Lane S, Hanslik T, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007 Feb;66(2):222–227
  5. Scott DG, Watts RA. Classification and epidemiology of systemic vasculitis. Br J Rheumatol. 1994 Oct;33(10):897–899
  6. Ozen S, Ruperto N, Dillon MJ, et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis. 2006 Jul;65(7):936–941
  7. Choi HK, Liu S, Merkel PA, et al. Diagnostic performance of antineutrophil cytoplasmic antibody tests for idiopathic vasculitides: metaanalysis with a focus on antimyeloperoxidase antibodies. J Rheumatol. 2001 Jul;28(7):1584–1590
  8. Mukhtyar C, Flossmann O, Hellmich B, et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis. 2008 Jul;67(7):1004–1010
  9. Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R, Gross WL. Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register. Arthritis Rheum. 2005 Feb 15;53(1):93–99
  10. Watts RA, Lane S, Scott DG. What is known about the epidemiology of the vasculitides?. Best Pract Res Clin Rheumatol. 2005 Apr;19(2):191–207
  11. Watts RA, Jolliffe VA, Carruthers DM, et al. Effect of classification on the incidence of polyarteritis nodosa and microscopic polyangiitis. Arthritis Rheum. 1996 Jul;39(7):1208–1212
  12. Donald KJ, Edwards RL, McEvoy JD. An ultrastructural study of the pathogenesis of tissue injury in limited Wegener's granulomatosis. Pathology. 1976 Apr;8(2):161–169
  13. Kissel JT, Riethman JL, Omerza J, et al. Peripheral nerve vasculitis: immune characterization of the vascular lesions. Ann Neurol. 1989 Mar;25(3):291–297
  14. Savage CO. The evolving pathogenesis of systemic vasculitis. Clin Med. 2002 Sep–Oct;2(5):458–464
  15. Belizna C, Duijvestijn A, Hamidou M, Cohen Tervaert JW. Antiendothelial cell antibodies in vasculitis and connective tissue disease. Ann Rheum Dis. 2006 Dec;65(12):1545–1550
  16. Cid MC. Endothelial cell biology, perivascular inflammation, and vasculitis. Cleve Clin J Med. 2002;69(Suppl. 2):SII45–SII49
  17. Myllykangas-Luosujarvi R, Aho K, Kautiainen H, Isomaki H. Cardiovascular mortality in women with rheumatoid arthritis. J Rheumatol. 1995 Jun;22(6):1065–1067
  18. Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum. 1999 Feb;42(2):338–346
  19. Bacon PA, Townend JN. Nails in the coffin: increasing evidence for the role of rheumatic disease in the cardiovascular mortality of rheumatoid arthritis. Arthritis Rheum. 2001 Dec;44(12):2707–2710
  20. Gordon M, Luqmani RA, Adu D, et al. Relapses in patients with a systemic vasculitis. Q J Med. 1993 Dec;86(12):779–789
  21. Morrow DA, Rifai N, Antman EM, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. 1998 Jun;31(7):1460–1465
  22. Seyahi E, Ugurlu S, Cumali R, et al. Atherosclerosis in Takayasu arteritis. Ann Rheum Dis. 2006 Sep;65(9):1202–1207
  23. Kim SY, Park JH, Chung JW, et al. Follow-up CT evaluation of the mural changes in active Takayasu arteritis. Korean J Radiol. 2007 Jul–Aug;8(4):286–294
  24. Dhillon R, Clarkson P, Donald AE, et al. Endothelial dysfunction late after Kawasaki disease. Circulation. 1996 Nov 1;94(9):2103–2106
  25. Ikemoto Y, Ogino H, Teraguchi M, Kobayashi Y. Evaluation of preclinical atherosclerosis by flow-mediated dilatation of the brachial artery and carotid artery analysis in patients with a history of Kawasaki disease. Pediatr Cardiol. 2005 Nov–Dec;26(6):782–786
  26. McCrindle BW, McIntyre S, Kim C, et al. Are patients after Kawasaki disease at increased risk for accelerated atherosclerosis?. J Pediatr. 2007 Sep;151(3):244–2488 e1
  27. Pilla CB. Chronically reduced arterial distensibility in Kawasaki disease: further evidence for the beneficial effects of immunoglobulin. Circulation. 2000;102(Suppl. II):830
  28. Cheung YF, Ho MH, Tam SC, Yung TC. Increased high sensitivity C reactive protein concentrations and increased arterial stiffness in children with a history of Kawasaki disease. Heart. 2004 Nov;90(11):1281–1285
  29. Cheung YF, Wong SJ, Ho MH. Relationship between carotid intima-media thickness and arterial stiffness in children after Kawasaki disease. Arch Dis Child. 2007 Jan;92(1):43–47
  30. Dalla Pozza R, Bechtold S, Urschel S, et al. Subclinical atherosclerosis, but normal autonomic function after Kawasaki disease. J Pediatr. 2007 Sep;151(3):239–243
  31. Blockmans D, de Ceuninck L, Vanderschueren S, et al. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum. 2006 Feb 15;55(1):131–137
  32. Filer AD, Gardner-Medwin JM, Thambyrajah J, et al. Diffuse endothelial dysfunction is common to ANCA associated systemic vasculitis and polyarteritis nodosa. Ann Rheum Dis. 2003 Feb;62(2):162–167
  33. Booth AD, Jayne DR, Kharbanda RK, et al. Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Circulation. 2004 Apr 13;109(14):1718–1723
  34. Gonzalez-Juanatey C, Llorca J, Garcia-Porrua C, et al. Steroid therapy improves endothelial function in patients with biopsy-proven giant cell arteritis. J Rheumatol. 2006 Jan;33(1):74–78
  35. Tso E, Flamm SD, White RD, et al. Takayasu arteritis: utility and limitations of magnetic resonance imaging in diagnosis and treatment. Arthritis Rheum. 2002 Jun;46(6):1634–1642
  36. Sharma BK, Jain S, Radotra BD. An autopsy study of Takayasu arteritis in India. Int J Cardiol. 1998 Oct 1;66(Suppl. 1):S85–S90(discussion S1)
  37. Lehtinen AB, Burdon KP, Lewis JP, et al. Association of alpha2-Heremans-Schmid glycoprotein polymorphisms with subclinical atherosclerosis. J Clin Endocrinol Metab. 2007 Jan;92(1):345–352
  38. Proven A, Gabriel SE, Orces C, et al. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum. 2003 Oct 15;49(5):703–708
  39. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR Recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2008 Apr 15;
  40. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR Recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2008 Apr 15;
  41. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003 Jul 3;349(1):36–44
  42. Watts RA, Scott DGI. Epidemiology of vasculitis. In:  Ball GV,  Bridges SL editor. Vasculitis. 2nd edn.. Oxford: Oxford University Press; 2008;p. 7–22
  43. Nuenninghoff DM, Hunder GG, Christianson TJ, et al. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum. 2003 Dec;48(12):3522–3531
  44. Gelsomino S, Romagnoli S, Gori F, et al. Annuloaortic ectasia and giant cell arteritis. Ann Thorac Surg. 2005 Jul;80(1):101–105
  45. Evans JM, Bowles CA, Bjornsson J, et al. Thoracic aortic aneurysm and rupture in giant cell arteritis. A descriptive study of 41 cases. Arthritis Rheum. 1994 Oct;37(10):1539–1547
  46. Gonzalez-Gay MA, Garcia-Porrua C, Pineiro A, et al. Aortic aneurysm and dissection in patients with biopsy-proven giant cell arteritis from northwestern Spain: a population-based study. Medicine (Baltimore). 2004 Nov;83(6):335–341
  47. Evans JM, O'Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med. 1995 Apr 1;122(7):502–507
  48. Gonzalez-Gay MA, Rubiera G, Pineiro A, et al. Ischemic heart disease in patients from Northwest Spain with biopsy proven giant cell arteritis. A population based study. J Rheumatol. 2005 Mar;32(3):502–506
  49. Ray JG, Mamdani MM, Geerts WH. Giant cell arteritis and cardiovascular disease in older adults. Heart. 2005 Mar;91(3):324–328
  50. Martin JF, Kittas C, Triger DR. Giant cell arteritis of coronary arteries causing myocardial infarction. Br Heart J. 1980 Apr;43(4):487–489
  51. Pego-Reigosa R, Garcia-Porrua C, Pineiro A, et al. Predictors of cerebrovascular accidents in giant cell arteritis in a defined population. Clin Exp Rheumatol. 2004;22(6 Suppl. 36):S13–S17
  52. Yamada I, Shibuya H, Matsubara O, et al. Pulmonary artery disease in Takayasu's arteritis: angiographic findings. AJR Am J Roentgenol. 1992 Aug;159(2):263–269
  53. Cakar N, Yalcinkaya F, Duzova A, et al. Takayasu arteritis in children. J Rheumatol. 2008 May;35(5):913–919
  54. Panja M, Sarkar C, Kar AK, et al. Coronary artery lesions in Takayasu's arteritis–clinical and angiographic study. J Assoc Physicians India. 1998 Aug;46(8):678–681
  55. Matsubara O, Kuwata T, Nemoto T, et al. Coronary artery lesions in Takayasu arteritis: pathological considerations. Heart Vessels Suppl. 1992;7:26–31
  56. Soto ME, Espinola-Zavaleta N, Ramirez-Quito O, Reyes PA. Echocardiographic follow-up of patients with Takayasu's arteritis: five-year survival. Echocardiography. 2006 May;23(5):353–360
  57. Talwar KK, Kumar K, Chopra P, et al. Cardiac involvement in nonspecific aortoarteritis (Takayasu's arteritis). Am Heart J. 1991 Dec;122(6):1666–1670
  58. Brogan PA, Bose A, Burgner D, et al. Kawasaki disease: an evidence based approach to diagnosis, treatment, and proposals for future research. Arch Dis Child. 2002 Apr;86(4):286–290
  59. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics. 2004 Dec;114(6):1708–1733
  60. Dhillon R, Newton L, Rudd PT, Hall SM. Management of Kawasaki disease in the British Isles. Arch Dis Child. 1993 Dec;69(6):631–636(discussion 7–8)
  61. Tizard EJ. Recognition and management of Kawasaki diseasee. Curr Paediatr. 1999 Jun;9(2):97–101
  62. Newburger JW, Taubert KA, Shulman ST, et al. Summary and abstracts of the Seventh International Kawasaki Disease Symposium: December 4–7, 2001, Hakone, Japan. Pediatr Res. 2003 Jan;53(1):153–157
  63. Ozen S, Anton J, Arisoy N, et al. Juvenile polyarteritis: results of a multicenter survey of 110 children. J Pediatr. 2004 Oct;145(4):517–522
  64. Chirinos JA, Tamariz LJ, Lopes G, et al. Large vessel involvement in ANCA-associated vasculitides: report of a case and review of the literature. Clin Rheumatol. 2004 Apr;23(2):152–159
  65. Korantzopoulos P, Papaioannides D, Siogas K. The heart in Wegener's granulomatosis. Cardiology. 2004;102(1):7–10
  66. Aasarod K, Iversen BM, Hammerstrom J, et al. Wegener's granulomatosis: clinical course in 108 patients with renal involvement. Nephrol Dial Transplant. 2000 May;15(5):611–618
  67. Anderson G, Coles ET, Crane M, et al. Wegener's granuloma. A series of 265 British cases seen between 1975 and 1985. A report by a sub-committee of the British Thoracic Society Research Committee. Q J Med. 1992 Jun;83(302):427–438
  68. Koldingsnes W, Nossent JC. Baseline features and initial treatment as predictors of remission and relapse in Wegener's granulomatosis. J Rheumatol. 2003 Jan;30(1):80–88
  69. Bourgarit A, Le Toumelin P, Pagnoux C, et al. Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients. Medicine (Baltimore). 2005 Sep;84(5):323–330
  70. Brogan PA, Davies R, Gordon I, Dillon MJ. Renal angiography in children with polyarteritis nodosa. Pediatr Nephrol. 2002 Apr;17(4):277–283
  71. Brogan PA, Shah V, Dillon MJ. Polyarteritis Nodosa in childhood. Cleve Clin J Med. 2002;69(Suppl. 2):SII-168–SII-169
  72. Cheung YF, Brogan PA, Pilla CB, et al. Arterial distensibility in children and teenagers: normal evolution and the effect of childhood vasculitis. Arch Dis Child. 2002 Oct;87(4):348–351
  73. Saulsbury FT. Clinical update: Henoch-Schonlein purpura. Lancet. 2007 Mar 24;369(9566):976–978
  74. Gedalia A. Henoch-Schonlein purpura. Curr Rheumatol Rep. 2004 Jun;6(3):195–202
  75. Gardner-Medwin JM, Dolezalova P, Cummins C, Southwood TR. Incidence of Henoch-Schonlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet. 2002 Oct 19;360(9341):1197–1202
  76. Brogan PA. What's new in the aetiopathogenesis of vasculitis?. Pediatr Nephrol. 2007 Aug;22(8):1083–1094
  77. Dillon MJ. Henoch-Schonlein purpura: recent advances. Clin Exp Rheumatol. 2007 Jan–Feb;25(1 Suppl. 44):S66–S68
  78. Ronkainen J, Nuutinen M, Koskimies O. The adult kidney 24 years after childhood Henoch-Schonlein purpura: a retrospective cohort study. Lancet. 2002 Aug 31;360(9334):666–670
  79. Rees L, Webb NJA, Brogan PA. Henoch Schonlein Purpura. Paediatric Nephrology. Oxford: Oxford University Press; 2007;p. 310–13
  80. Mahr AD, Jover JA, Spiera RF, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 2007 Aug;56(8):2789–2797
  81. Brogan PA, Shah V, Clarke LA, et al. T cell activation profiles in Kawasaki syndrome. Clin Exp Immunol. 2008 Feb;151(2):267–274
  82. Gandhi A, Wilson DG. Incomplete Kawasaki disease: not to be forgotten. Arch Dis Child. 2006 Mar;91(3):276–277
  83. Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum. 2007 Mar;56(3):1000–1009
  84. Tada Y, Sato O, Ohshima A, et al. Surgical treatment of Takayasu arteritis. Heart Vessels Suppl. 1992;7:159–167
  85. Lagneau P, Michel JB. Renovascular hypertension and Takayasu's disease. J Urol. 1985 Nov;134(5):876–879
  86. Sharma S, Saxena A, Talwar KK, et al. Renal artery stenosis caused by nonspecific arteritis (Takayasu disease): results of treatment with percutaneous transluminal angioplasty. AJR Am J Roentgenol. 1992 Feb;158(2):417–422
  87. Fields CE, Bower TC, Cooper LT, et al. Takayasu's arteritis: operative results and influence of disease activity. J Vasc Surg. 2006 Jan;43(1):64–71
  88. Hellmich B, Flossmann O, Gross WL, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis. 2007 May;66(5):605–617
  89. Jayne D. Update on the European Vasculitis Study Group trials. Curr Opin Rheumatol. 2001 Jan;13(1):48–55

PII: S1521-6942(09)00023-0

doi: 10.1016/j.berh.2009.02.002

Best Practice & Research Clinical Rheumatology
Volume 23, Issue 3 , Pages 419-428 , June 2009

Article Tools